Clopidogrel News and Research

RSS
Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
Trial examines differences in gastrointestinal effects of antiplatelet therapy after PCI

Trial examines differences in gastrointestinal effects of antiplatelet therapy after PCI

Research reveals a new role for platelets in COVID-19 blood vessel damage

Research reveals a new role for platelets in COVID-19 blood vessel damage

Trial tests effectiveness of two prospective stroke therapies over standard of care

Trial tests effectiveness of two prospective stroke therapies over standard of care

ESO guidelines focus on early management of transient ischemic attack

ESO guidelines focus on early management of transient ischemic attack

Study highlights the role of genetic testing in evaluation of in-stent thrombosis

Study highlights the role of genetic testing in evaluation of in-stent thrombosis

Potent antiplatelet drug not superior to standard of care in reducing heart attack risk during angioplasty

Potent antiplatelet drug not superior to standard of care in reducing heart attack risk during angioplasty

Study shows best antiplatelet treatment after transcatheter aortic valve implantation

Study shows best antiplatelet treatment after transcatheter aortic valve implantation

Personalized genetic testing helps reduce adverse events following balloon angioplasty

Personalized genetic testing helps reduce adverse events following balloon angioplasty

Precision medicine can determine the best drug treatment for severe heart disease

Precision medicine can determine the best drug treatment for severe heart disease

Study provides indications and techniques of lower extremity revascularization

Study provides indications and techniques of lower extremity revascularization

Clopidogrel added to aspirin and rvaroxaban shows no additional benefit for peripheral artery disease

Clopidogrel added to aspirin and rvaroxaban shows no additional benefit for peripheral artery disease

Clinical trial using genetic testing to guide antiplatelet therapy post-PCI falls short of stated goal

Clinical trial using genetic testing to guide antiplatelet therapy post-PCI falls short of stated goal

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

Adding antiplatelet therapy to oral anticoagulants raises risk for TAVR patients with atrial fibrillation

Adding antiplatelet therapy to oral anticoagulants raises risk for TAVR patients with atrial fibrillation

Partnership between medical specialties helps improve cardiovascular health

Partnership between medical specialties helps improve cardiovascular health

Edoxaban-based dual therapy noninferior to standard treatment in atrial fibrillation post-stenting

Edoxaban-based dual therapy noninferior to standard treatment in atrial fibrillation post-stenting

People with stroke can take common medicines without raising risk of another stroke

People with stroke can take common medicines without raising risk of another stroke

Scientists solve mystery surrounding mechanical forces that influence blood clotting

Scientists solve mystery surrounding mechanical forces that influence blood clotting

Study shows ticagrelor is equally safe and effective as clopidogrel after heart attack

Study shows ticagrelor is equally safe and effective as clopidogrel after heart attack

Study indicates the benefits of stopping aspirin in heart attack patients

Study indicates the benefits of stopping aspirin in heart attack patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.